Cannabics Pharmaceuticals has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors.
Dr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company's clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
The patent protection of new disease specific and patient specific cannabinoid compositions and treatment protocols has already begun, with these four patent applications filed this month alone, with several and more in progress.
"Cannabics is broadening its potential offerings to the healthcare industry. We believe that the company's expertise in clinical evaluation of cannabinoid formulations has now been brought to bear in designing specific drugs and treatments which will potentially benefit many patients globally," Dr. Eyal Ballan, CTO and Co-Founder, said.